Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Osteoarthritis Cartilage ; 25(10): 1698-1707, 2017 10.
Artículo en Inglés | MEDLINE | ID: mdl-28647469

RESUMEN

OBJECTIVE: Disruptions of extracellular matrix (ECM) homeostasis are key events in the pathogenesis of osteoarthritis (OA). MicroRNA-140 (miRNA-140) is expressed specifically in cartilage and regulates ECM-degrading enzymes. Our objective in this study was to determine if intra-articular injection of miRNA-140 can attenuate OA progression in rats. DESIGN: miRNA-140 levels in human normal and OA cartilage derived chondrocytes and synovial fluid were assessed by polymerase chain reaction (PCR). After primary human chondrocytes were transfected with miRNA-140 mimic or inhibitor, PCR and western blotting were performed to quantify Collagen II, MMP-13, and ADAMTS-5 expression. An OA model was induced surgically in rats, and subsequently treated with one single intra-articular injection of miRNA-140 agomir. At 4, 8, and 12 weeks after surgery, OA progression were evaluated macroscopically, histologically, and immunohistochemically in these rats. RESULTS: miRNA-140 levels were significantly reduced in human OA cartilage derived chondrocytes and synovial fluid compared with normal chondrocytes and synovial fluid. Overexpressing miRNA-140 in primary human chondrocytes promoted Collagen II expression and inhibited MMP-13 and ADAMTS-5 expression. miRNA-140 levels in rat cartilage were significantly higher in the miRNA-140 agomir group than in the control group. Moreover, behavioural scores, chondrocyte numbers, cartilage thickness and Collagen II expression levels in cartilage were significantly higher, while pathological scores and MMP-13 and ADAMTS-5 expression levels were significantly lower in the miRNA-140 agomir group than in the control group. CONCLUSION: Intra-articular injection of miRNA-140 can alleviate OA progression by modulating ECM homeostasis in rats, and may have potential as a new therapy for OA.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Matriz Extracelular/efectos de los fármacos , MicroARNs/administración & dosificación , Osteoartritis/tratamiento farmacológico , Proteína ADAMTS5/biosíntesis , Proteína ADAMTS5/genética , Adulto , Anciano , Anciano de 80 o más Años , Animales , Artritis Experimental/metabolismo , Artritis Experimental/patología , Cartílago Articular/metabolismo , Cartílago Articular/patología , Células Cultivadas , Condrocitos/metabolismo , Colágeno Tipo II/biosíntesis , Colágeno Tipo II/genética , Progresión de la Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Matriz Extracelular/fisiología , Regulación de la Expresión Génica/fisiología , Homeostasis/efectos de los fármacos , Humanos , Inyecciones Intraarticulares , Masculino , Metaloproteinasa 13 de la Matriz/biosíntesis , Metaloproteinasa 13 de la Matriz/genética , MicroARNs/metabolismo , MicroARNs/farmacología , MicroARNs/uso terapéutico , Persona de Mediana Edad , Osteoartritis/metabolismo , Osteoartritis/patología , Ratas Sprague-Dawley , Líquido Sinovial/metabolismo , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA